Active, Not Recruiting
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06693843
- Conditions
- Body Weight, Nutrition Disorders, Nutritional and Metabolic Diseases, +6 more
- Locations
-
- ACCESS Research Site Phoenix, Arizona, United States
- ACCESS Research Site Anaheim, California, United States
- ACCESS Research Site Los Angeles, California, United States
- ACCESS Research Site Montclair, California, United States